Literature DB >> 21679828

Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis.

Anja Gunda Jung, Hans-Peter Horny, Karl Sotlar, Tobias Overbeck, Michael Peter Schön, Undine Lippert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21679828     DOI： 10.1016/j.jaad.2009.11.034

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  2 in total

Review 1.  [Mastocytosis : Clinical aspects, diagnostics, therapy].

Authors:  U Lippert
Journal:  Hautarzt       Date:  2017-01       Impact factor: 0.751

2.  Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature.

Authors:  Iván Alvarez-Twose; Almudena Matito; José Mário Morgado; Laura Sánchez-Muñoz; María Jara-Acevedo; Andrés García-Montero; Andrea Mayado; Carolina Caldas; Cristina Teodósio; Javier Ignacio Muñoz-González; Manuela Mollejo; Luis Escribano; Alberto Orfao
Journal:  Oncotarget       Date:  2016-07-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.